Ipca Laboratories shareholders approve all resolutions at 76th AGM

Shareholders of Ipca Laboratories approved all resolutions placed before them at the company’s 76th annual general meeting (AGM) held on August 13, 2026. The meeting, conducted via video conferencing and remote e-voting, saw the passage of ordinary resolutions regarding financial statements, dividends, and board appointments.

A total of 85,465 shareholders were on record as of the cut-off date, August 7, 2026. Of these, 57 shareholders attended the meeting through video conferencing, comprising 10 from the promoter group and 47 public shareholders. No shareholders were present in person or through proxy.

Voting Results Overview

The promoters, holding 113,467,472 shares, voted in favor of all resolutions. Public institutional holders, with 121,367,491 shares, also largely supported the agenda items, while public others held 18,869,255 shares.

Resolution	Promoter Votes In Favor	Public Institutional Votes In Favor	Total Votes Polled	% In Favor
Adoption of Financial Statements (FY26)	113,467,472	116,489,560	230,284,613	99.98%
Dividend Declaration	113,467,472	116,549,044	230,303,593	99.99%
Re-appointment of Ajit Kumar Jain	113,467,472	115,201,064	230,303,393	99.41%
Re-appointment of Pranay Godha	113,467,472	115,284,003	230,303,393	99.45%
Re-appointment of Prashant Godha	113,467,472	94,108,914	230,303,593	90.26%
Cost Auditor Remuneration	113,467,472	116,549,044	230,303,593	99.99%

Key Resolutions Passed

The first resolution involved the adoption of the audited financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors. This resolution received 99.98% of the votes polled in its favor.

The second resolution authorized the declaration of a dividend on equity shares. It was approved with 99.99% of the votes cast in favor. The promoter group voted unanimously for this resolution, as did nearly all public institutional holders.

Board Appointments

The AGM saw the re-appointment of three directors:

Ajit Kumar Jain (DIN 00012657): Re-appointed as a Director. The resolution passed with 99.41% approval. Public institutional holders showed slight dissent, with 1,347,980 votes against.
Pranay Godha (DIN 00016525): Re-appointed as a Director. The resolution secured 99.45% approval. Similar to Mr. Jain’s re-appointment, some institutional dissent was recorded.
Prashant Godha (DIN 00012759): Re-appointed as Executive Director for a further period of five years commencing August 16, 2026. This resolution received the lowest support among the agenda items, with 90.26% of votes in favor. Notably, public institutional holders cast 22,440,130 votes against this resolution, representing 19.25% of their polled votes.

Other Matters

The final resolution ratified the remuneration payable to M/s. ABK & Associates, Cost Accountants (Firm Registration No. 000036), for conducting the cost audit for FY27. This proposal was approved with 99.99% of the votes polled.

Ms. Jigyasa N. Ved of M/s. Parikh & Associates served as the scrutinizer for the AGM. The e-voting facility was provided by National Securities Depository Limited (NSDL), with the voting period running from August 10 to August 12, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.40%	+0.06%	-4.83%	+16.82%	+27.16%	+45.48%

IPCA Laboratories reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit rising to ₹4,019 crore compared to ₹2,332 crore in the corresponding period last year. The company’s revenue also strengthened, reaching ₹27,881 crore versus ₹23,089 crore year-on-year, reflecting robust top-line growth alongside operational efficiency gains.

The firm’s operating performance showed marked acceleration, with EBITDA (before forex gain/loss and other income) jumping to ₹6,379 crore from ₹4,246 crore in the prior year. This represents a substantial expansion in operating leverage, as the EBITDA margin widened to 22.88% from 18.39% in the previous quarter.

Financial Highlights

Metric:	Q1FY27	Q1FY26	Change
Revenue:	₹27,881 crore	₹23,089 crore	+21%
EBITDA (before forex/other income):	₹6,379 crore	₹4,246 crore	+50%
EBITDA Margin:	22.88%	18.39%	+449 bps
Net Profit (Consolidated):	₹4,019 crore	₹2,332 crore	+72%

Segment Performance

Export-led growth was the primary driver for the quarter. Export income surged 34% to ₹9,354 crore, while domestic formulations income grew 13% to ₹10,821 crore. Within exports, institutional sales saw the sharpest rise, growing 107% to ₹1,198 crore, followed by generics at 27% growth to ₹3,400 crore.

Standalone results also reflected strong momentum, with standalone net profit rising 42% to ₹3,733 crore. Standalone revenue from operations increased 21% to ₹21,192 crore. The standalone EBITDA margin expanded to 26.27% from 23.82% in Q1FY26.

What the Numbers Show

The divergence between revenue growth and profit expansion highlights improved cost management or product mix optimization. While consolidated revenue increased by approximately 21%, net profit surged by over 72%, indicating that the company retained a larger share of each rupee earned. The nearly 5 percentage point jump in EBITDA margin suggests that operating expenses did not scale proportionally with sales, allowing for greater earnings conversion during the period. Additionally, finance costs declined 36% to ₹119 crore, further supporting bottom-line growth.